Cargando…
Microfluidic system for near-patient extraction and detection of miR-122 microRNA biomarker for drug-induced liver injury diagnostics
Drug-induced liver injury (DILI) results in over 100 000 hospital attendances per year in the UK alone and is a leading cause for the post-marketing withdrawal of new drugs, leading to significant financial losses. MicroRNA-122 (miR-122) has been proposed as a sensitive DILI marker although no comme...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AIP Publishing LLC
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018095/ https://www.ncbi.nlm.nih.gov/pubmed/35464137 http://dx.doi.org/10.1063/5.0085078 |
_version_ | 1784688935844184064 |
---|---|
author | Kersaudy-Kerhoas, Maïwenn Liga, Antonio Roychoudhury, Appan Stamouli, Marilena Grant, Rhiannon Carrera, Damaso Sanchez Schulze, Holger Mielczarek, Witold Oosthuyzen, Wilna Quintana, Juan F. Dickinson, Paul Buck, Amy H. Leslie, Nicholas R. Haas, Jurgen Bachmann, Till T. Dear, James W. |
author_facet | Kersaudy-Kerhoas, Maïwenn Liga, Antonio Roychoudhury, Appan Stamouli, Marilena Grant, Rhiannon Carrera, Damaso Sanchez Schulze, Holger Mielczarek, Witold Oosthuyzen, Wilna Quintana, Juan F. Dickinson, Paul Buck, Amy H. Leslie, Nicholas R. Haas, Jurgen Bachmann, Till T. Dear, James W. |
author_sort | Kersaudy-Kerhoas, Maïwenn |
collection | PubMed |
description | Drug-induced liver injury (DILI) results in over 100 000 hospital attendances per year in the UK alone and is a leading cause for the post-marketing withdrawal of new drugs, leading to significant financial losses. MicroRNA-122 (miR-122) has been proposed as a sensitive DILI marker although no commercial applications are available yet. Extracellular blood microRNAs (miRNAs) are promising clinical biomarkers but their measurement at point of care remains time-consuming, technically challenging, and expensive. For circulating miRNA to have an impact on healthcare, a key challenge to overcome is the development of rapid and reliable low-cost sample preparation. There is an acknowledged issue with miRNA stability in the presence of hemolysis and platelet activation, and no solution has been demonstrated for fast and robust extraction at the site of blood draw. Here, we report a novel microfluidic platform for the extraction of circulating miR-122 from blood enabled by a vertical approach and gravity-based bubble mixing. The performance of this disposable cartridge was verified by standard quantitative polymerase chain reaction analysis on extracted miR-122. The cartridge performed equivalently or better than standard bench extraction kits. The extraction cartridge was combined with electrochemical impedance spectroscopy to detect miR-122 as an initial proof-of-concept toward an application in point-of-care detection. This platform enables the standardization of sample preparation and the detection of miRNAs at the point of blood draw and in resource limited settings and could aid the introduction of miRNA-based assays into routine clinical practice. |
format | Online Article Text |
id | pubmed-9018095 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | AIP Publishing LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-90180952022-04-22 Microfluidic system for near-patient extraction and detection of miR-122 microRNA biomarker for drug-induced liver injury diagnostics Kersaudy-Kerhoas, Maïwenn Liga, Antonio Roychoudhury, Appan Stamouli, Marilena Grant, Rhiannon Carrera, Damaso Sanchez Schulze, Holger Mielczarek, Witold Oosthuyzen, Wilna Quintana, Juan F. Dickinson, Paul Buck, Amy H. Leslie, Nicholas R. Haas, Jurgen Bachmann, Till T. Dear, James W. Biomicrofluidics Regular Articles Drug-induced liver injury (DILI) results in over 100 000 hospital attendances per year in the UK alone and is a leading cause for the post-marketing withdrawal of new drugs, leading to significant financial losses. MicroRNA-122 (miR-122) has been proposed as a sensitive DILI marker although no commercial applications are available yet. Extracellular blood microRNAs (miRNAs) are promising clinical biomarkers but their measurement at point of care remains time-consuming, technically challenging, and expensive. For circulating miRNA to have an impact on healthcare, a key challenge to overcome is the development of rapid and reliable low-cost sample preparation. There is an acknowledged issue with miRNA stability in the presence of hemolysis and platelet activation, and no solution has been demonstrated for fast and robust extraction at the site of blood draw. Here, we report a novel microfluidic platform for the extraction of circulating miR-122 from blood enabled by a vertical approach and gravity-based bubble mixing. The performance of this disposable cartridge was verified by standard quantitative polymerase chain reaction analysis on extracted miR-122. The cartridge performed equivalently or better than standard bench extraction kits. The extraction cartridge was combined with electrochemical impedance spectroscopy to detect miR-122 as an initial proof-of-concept toward an application in point-of-care detection. This platform enables the standardization of sample preparation and the detection of miRNAs at the point of blood draw and in resource limited settings and could aid the introduction of miRNA-based assays into routine clinical practice. AIP Publishing LLC 2022-04-18 /pmc/articles/PMC9018095/ /pubmed/35464137 http://dx.doi.org/10.1063/5.0085078 Text en © 2022 Author(s). https://creativecommons.org/licenses/by/4.0/All article content, except where otherwise noted, is licensed under a Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). Published open access through an agreement withJISC Collections128554 |
spellingShingle | Regular Articles Kersaudy-Kerhoas, Maïwenn Liga, Antonio Roychoudhury, Appan Stamouli, Marilena Grant, Rhiannon Carrera, Damaso Sanchez Schulze, Holger Mielczarek, Witold Oosthuyzen, Wilna Quintana, Juan F. Dickinson, Paul Buck, Amy H. Leslie, Nicholas R. Haas, Jurgen Bachmann, Till T. Dear, James W. Microfluidic system for near-patient extraction and detection of miR-122 microRNA biomarker for drug-induced liver injury diagnostics |
title | Microfluidic system for near-patient extraction and detection of miR-122 microRNA biomarker for drug-induced liver injury diagnostics |
title_full | Microfluidic system for near-patient extraction and detection of miR-122 microRNA biomarker for drug-induced liver injury diagnostics |
title_fullStr | Microfluidic system for near-patient extraction and detection of miR-122 microRNA biomarker for drug-induced liver injury diagnostics |
title_full_unstemmed | Microfluidic system for near-patient extraction and detection of miR-122 microRNA biomarker for drug-induced liver injury diagnostics |
title_short | Microfluidic system for near-patient extraction and detection of miR-122 microRNA biomarker for drug-induced liver injury diagnostics |
title_sort | microfluidic system for near-patient extraction and detection of mir-122 microrna biomarker for drug-induced liver injury diagnostics |
topic | Regular Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018095/ https://www.ncbi.nlm.nih.gov/pubmed/35464137 http://dx.doi.org/10.1063/5.0085078 |
work_keys_str_mv | AT kersaudykerhoasmaiwenn microfluidicsystemfornearpatientextractionanddetectionofmir122micrornabiomarkerfordruginducedliverinjurydiagnostics AT ligaantonio microfluidicsystemfornearpatientextractionanddetectionofmir122micrornabiomarkerfordruginducedliverinjurydiagnostics AT roychoudhuryappan microfluidicsystemfornearpatientextractionanddetectionofmir122micrornabiomarkerfordruginducedliverinjurydiagnostics AT stamoulimarilena microfluidicsystemfornearpatientextractionanddetectionofmir122micrornabiomarkerfordruginducedliverinjurydiagnostics AT grantrhiannon microfluidicsystemfornearpatientextractionanddetectionofmir122micrornabiomarkerfordruginducedliverinjurydiagnostics AT carreradamasosanchez microfluidicsystemfornearpatientextractionanddetectionofmir122micrornabiomarkerfordruginducedliverinjurydiagnostics AT schulzeholger microfluidicsystemfornearpatientextractionanddetectionofmir122micrornabiomarkerfordruginducedliverinjurydiagnostics AT mielczarekwitold microfluidicsystemfornearpatientextractionanddetectionofmir122micrornabiomarkerfordruginducedliverinjurydiagnostics AT oosthuyzenwilna microfluidicsystemfornearpatientextractionanddetectionofmir122micrornabiomarkerfordruginducedliverinjurydiagnostics AT quintanajuanf microfluidicsystemfornearpatientextractionanddetectionofmir122micrornabiomarkerfordruginducedliverinjurydiagnostics AT dickinsonpaul microfluidicsystemfornearpatientextractionanddetectionofmir122micrornabiomarkerfordruginducedliverinjurydiagnostics AT buckamyh microfluidicsystemfornearpatientextractionanddetectionofmir122micrornabiomarkerfordruginducedliverinjurydiagnostics AT leslienicholasr microfluidicsystemfornearpatientextractionanddetectionofmir122micrornabiomarkerfordruginducedliverinjurydiagnostics AT haasjurgen microfluidicsystemfornearpatientextractionanddetectionofmir122micrornabiomarkerfordruginducedliverinjurydiagnostics AT bachmanntillt microfluidicsystemfornearpatientextractionanddetectionofmir122micrornabiomarkerfordruginducedliverinjurydiagnostics AT dearjamesw microfluidicsystemfornearpatientextractionanddetectionofmir122micrornabiomarkerfordruginducedliverinjurydiagnostics |